Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.79) by 10.13 percent. This is a 2.35 percent decrease over losses of $(0.85) per share from the same period last year.
Microsoft’s Renewable Energy Leap: A Game Changer?
Microsoft solidifies its commitment to sustainability with agreement backing renewable energy projects by Brookfield Asset Management.
